anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Gastroesophageal reflux is considered to be a common cause of cricopharyngeal dysfunction and Zenker's diverticulum. In patients with severe symptoms of dysphagia, we perform a cricopharyngeal myotomy to release the tension at the upper esophageal sphincter. There has been some speculation that if the upper esophageal sphincter is severed, there could be an increase in reflux into the pharyngeal and laryngeal structures. The current gold standard for measuring laryngopharyngeal reflux (LPR) is 24 hour monitoring with a dual-electrode pH catheter. A newer device specifically measures LPR by sitting in the nasopharynx. The probe has been verified as accurate by several studies, with some postulating that since its recording intervals are closer together, it may be more accurate for measuring LPR. We aim to measure LPR with the new pH probe in patients with gastroesophageal reflux before and after cricopharyngeal myotomy to see if LPR becomes present or worsens after surgery.

All patients presenting with cricopharyngeal dysfunction or Zenker's diverticulum with a diagnosis or symptoms of gastroesophageal reflux or laryngopharyngeal reflux will be asked to participate in the study. If they meet the inclusion criteria, agree to participate, and wish to undergo surgery for their dysphagia, a baseline 24 hr laryngopharyngeal reflux study will be obtained using the Restech probe. Additionally, baseline dysphagia and reflux questionnaires will be obtained and an exam with flexible nasopharyngoscopy will be done. This exam is considered part of a standard exam for this condition and would be performed even if patients were not part of the research study. The surgical procedure will treat their dysphagia no differently than if they were not participating in the study. The patient will have their standard postoperative visit at 4 weeks, where their reflux and dysphagia symptoms will be assessed with questionnaires and a reflux finding score will be calculated via nasopharyngoscopy. At 3 months, an additional 24 laryngopharyngeal reflux study will be conducted with the Restech probe, and the patient will be seen in clinic for their final postoperative visit shortly thereafter. The questionnaires and the flexible nasopharyngoscopy for a reflux finding score will be repeated. The nasopharyngoscopy exam is standard of care for this patient visit. The patient would undergo the same number of nasopharyngoscopies even if they were not part of the study. During the study, if the patient is already on medication for reflux, they will be taken off their medication for 7 days in order to better detect changes in their LPR before and after cricopharyngeal myotomy. This is the standard protocol for patients being tested for LPR by the 24 hr pH probe study with the Restech probe. The patients will serve as their own controls as we are looking for significant increases in the amount of laryngopharyngeal reflux after cricopharyngeal myotomy. The data will be maintained in a database until the end of the study.
This is our standard breast milk fortification in our NICU. One packet (5 mL) of Similac Human Milk Fortifier Concentrated Liquid is added to breast milk feedings when infants reach 100 ml/kg/day. A second packet is added the next day (10 mL total), to make 24 kcal/oz. After infants reach full feedings (160 ml/kg/d), 3 ml/kg of Similac Liquid Protein Fortifier is added (0.5 g/kg protein). This is increased to 6 ml/kg (1 g/kg protein) the next day.
A conjoined twin is a subset of monozygotic twin gestation. It's a rare phenomenon with an incidence of 1 in 50,000 to 1:100,000 births with the higher incidence in Africa and Southwest Asia. Based on the terminology proposed by Spencer and colleagues, conjoined twins are classified according to the most prominent site of conjunction into three major groups; First, twins with a ventral union; \[cephalopagus (head), thoracopagus (Thorax), omphalopagus (Abdomen) and ischiopagus (pelvis)\]. Second; twins with a dorsal union; \[pygopagus (sacrum), rachipagus (spine, back) and craniopagus (cranium)\] and lastly; twins with a lateral union that is referred to as parapagus (side). Depending on the aspect of the embryonic disc, the most common types are thoracopagus (19%).

Surgical separation of conjoined twins is extremely challenging taking in consideration the high perioperative risk. The low incidence of such surgeries and anatomical variations in each type of conjoined twins makes each separation surgery a unique experience.
Two-thirds of people living with HIV show sub-optimal adherence to antiretroviral therapy (ART) and one-third engages in risky sex. Both non-adherence and risky sex have been associated with emotional distress and impulsivity. In this trial, the investigators will examine the utility of phone-delivered mindfulness training (MT) for people living with HIV. The primary outcomes comprise feasibility and acceptability of phone-delivery; secondary outcomes are estimates of efficacy of MT on adherence to ART and safer sexual practices as well as on their hypothesized antecedents.

Fifty participants will be enrolled in this parallel-group randomized clinical trial (RCT). Outpatients recruited from an HIV treatment clinic will be randomized (1:1 ratio) to either MT or to health coaching intervention; both interventions will be administered during 8 weekly phone calls. ART adherence (self-reported measure and unannounced phone pill counts), sexual behavior (self-reports and biomarkers), mindfulness, depression, stress, and impulsivity will be measured at baseline, post-intervention, and 3 months post-intervention.
Methods and system for treatment planning for non- and minimally-invasive alteration of body adipose tissue for reduction and contouring of body fat are described herein. Treatment plans can be generated by capturing current body part data (e.g., positioning, contour/shape, thickness of adipose tissue, etc.), determining desired outcome of treatment (e.g., percent reduction of adipose tissue thickness, degree of contour change, etc.), and determining treatment parameters to achieve desired results. Algorithms can be used to determine best-fit treatment parameters to use in treatment sessions. In some embodiments, the system can provide a predictive end-result image for communication to patient and/or for determining alteration of desired outcome. In various embodiments, real-time monitoring of feedback data can be used to determine treatment plan efficacy. Additional algorithms can provide real-time comparison of feedback data to anticipated feedback data, and can be used to change treatment parameters in real-time to achieve desired effects.
INTRODUCTION: Intraoperative opioids have been used for decades to reduce negative responses to nociception. However, opioids may have several, and sometimes serious, adverse effects. Cardiac surgery exposes patients to a high risk of postoperative complications, some of which are common to those caused by opioids: acute respiratory failure, postoperative cognitive dysfunction, postoperative ileus (POI) or death. An opioid-free anaesthesia (OFA) strategy, based on the use of dexmedetomidine and lidocaine, may limit these adverse effects, but no randomised trials on this issue have been published in cardiac surgery.We hypothesised that OFA versus opioid-based anaesthesia (OBA) may reduce the incidence of major opioid-related complications after cardiac surgery.
METHODS AND ANALYSIS: Multicentre, randomised, parallel and single-blinded clinical trial in four cardiac surgical centres in France, including 268 patients scheduled for coronary artery bypass grafting under cardiac bypass, with or without aortic valve replacement. Patients will be randomised to either a control OBA protocol using remifentanil or an OFA protocol using dexmedetomidine/lidocaine. The primary composite endpoint is the occurrence of at least one of the following: (1) postoperative cognitive disorder evaluated by the Confusion Assessment Method for the Intensive Care Unit test, (2) POI, (3) acute respiratory distress or (4) death within the first 48 postoperative hours. Secondary endpoints are postoperative pain, morphine consumption, nausea-vomiting, shock, acute kidney injury, atrioventricular block, pneumonia and length of hospital stay.
ETHICS AND DISSEMINATION: This trial has been approved by an independent ethics committee (Comité de Protection des Personnes Ouest III-Angers on 23 February 2021). Results will be submitted in international journals for peer reviewing.
TRIAL REGISTRATION NUMBER: NCT04940689, EudraCT 2020-002126-90.
SHAKE WELL BEFORE USING. Two drops should be instilled into the conjunctival sac every four hours during the day and at bedtime. 

Not more than 20 milliliters should be prescribed initially, and the prescription should not be refilled without further evaluation as outlined in PRECAUTIONS above. 

BLEPHAMIDE® dosage may be reduced, but care should be taken not to discontinue therapy prematurely. In chronic conditions, withdrawal of treatment should be carried out by gradually decreasing the frequency of application. 

If signs and symptoms fail to improve after two days, the patient should be re-evaluated (see PRECAUTIONS).
A method for preparing cross-linked collagen and cross-linked collagen products. The method includes incubating collagen in a solution including water, at least one polar solvent and at least one sugar, to form cross-linked collagen. The solution may include a buffer having a suitable pH and ionic strength. The method may include removing excess unreacted sugar(s) and polar solvent(s) by washing the cross-linked collagen or by other methods. The method may also include dehydrating the cross-linked collagen, and may include subjecting the cross-linked collagen to critical point drying, or subjecting the collagen to drying or freeze-drying prior to cross-linking. The collagen may be prepared from atelopeptide collagen to reduce antigenicity, but may also be prepared from other suitable collagen types. The concentration and type of the polar solvent(s), the concentration and type of the reducing sugar(s), and the incubation duration may be varied to control the degree of cross-linking. The cross-linked collagen product may be in the form of a wet or dry matrix or membrane or may be suspended in a liquid in the form of an injectable preparation. The method may be applied to collagenous proteins and collagen-like peptides.
PURPOSE:To develop high complementary activity even by either one of antibody and antigen immobilizing method and to quantify the antigen or antibody in a specimen to be examined with high sensitivity by preparing a liposome using haptenized phospholipid as a constitutional component. CONSTITUTION:An antibody or antigen is immobilized on the surface of a liposome containing phospholipid, haptenized phospholipid and cholesterol as principal constitutional components and a hydrophilic marker substance is sealed in the liposome. At this time, the ratio of phospholipid and cholesterol being the principal constitutional components of the liposome is pref. about 1:1. Further, it is necessary that haptenized phospholipid is 0.005-0.1mol per 1mol of phospholipid. This reagent, a specimen containing the antigen or antibody and a complement are mixed in a buffer solution to bring about the bonding reaction of antigen-antibody and the complement. Whereupon, the marker substance is discharged from the liposome in proportion to reaction quantity. Next, determination is performed by an analytical method corresponding to the marker substance and, for example, by a preliminarily prepared calibration curve, the amount of the antibody or antigen in the specimen can be measured.
A composition, either as a nutritional supplement or pharmaceutical, for the treatment of oxidative stress, endothelial dysfunction and related disease states which comprises administration of D-chiroinositol (DCI) congeners, acting as an antioxidant or glucose uptake promoter and metabolic normalizer, is disclosed. A composition of treating oxidative stress comprising administration of DCI is also disclosed. The administration of DCI derivatives comprises administering to the whole animal a dose in an amount sufficient to normalize blood glucose and triglycerides and to ameliorate endothelial dysfunction. The administration can be an oral, injectable, intranasal, or patch dosage forms. DCI is found in the food chain and has been shown to be very safe in large doses and, therefore, the amounts sufficient to achieve the desired therapeutic antioxidant effect will be low relative to the amounts reaching toxic levels. Therefore, DCI can be administered orally as a prophylactic nutritional supplement.
The invention relates to medicine and pharmacology, and more particularly to development of ointments for treating and preventing pathologic vessel and tissue damages. The preparation can be used for treating diseases associated with venous insufficiency, varicose veins, thrombophlebitis, hemorrhoids, post-traumatic edemas and hematomas, dermatitis and trophic ulcers. The essence of the declared invention is that the developed vessel-strengthening agent, the ointment, contains the base and biologically active substance. The ointment contains spissum hazel extract as a biologically active substance; corn oil, emulsifier No. 1, polyethylene oxide 400, nipagin, nipasol as the base, remainder - purified water, with certain component ratio (g per 100 g). The technical effect of the claimed invention is that the set objective is achieved.
Magnesium is an essential ion in the human body that regulates numerous physiological and pathological processes. Magnesium deficiency is very common in old age. Age-related chronic diseases and the aging process itself are frequently associated with low-grade chronic inflammation, called 'inflammaging'. Because chronic magnesium insufficiency has been linked to excessive generation of inflammatory markers and free radicals, inducing a chronic inflammatory state, we formerly hypothesized that magnesium inadequacy may be considered among the intermediaries helping us explain the link between inflammaging and aging-associated diseases. We show in this review evidence of the relationship of magnesium with all the hallmarks of aging (genomic instability, telomere attrition, epigenetic alterations, loss of proteostasis, deregulated nutrient sensing, mitochondrial dysfunction, cellular senescence, stem cell exhaustion, altered intercellular communication, disabled autophagy, dysbiosis, and chronic inflammation), which may positively affect the human healthspan. It is feasible to hypothesize that maintaining an optimal balance of magnesium during one's life course may turn out to be a safe and economical strategy contributing to the promotion of healthy aging. Future well-designed studies are necessary to further explore this hypothesis.
Participants randomized to the control arm will not complete daily symptom screening. They will complete SSPedi on days 1 and 5 to obtain the primary outcome. Health care providers will not be notified of their SSPedi scores and no symptom reports or symptom alerts will be generated.
A 24-year-old man with classical Hodgkin lymphoma was lost to follow-up after metabolic complete remission (mCR). He presented 4 years later with B-symptoms and impaired clinical condition. Relapsed classical Hodgkin lymphoma was diagnosed. PET/CT revealed stage IVB with liver and spleen involvement. Two liver function-adjusted salvage attempts were ineffective. Pembrolizumab was instituted with gradual clinical improvement. PET was missed before treatment for a life-threatening condition and was performed on day +10 showing a near mCR. A mCR was confirmed before cycle 2, on day +21, underlining-for the first time in the literature-the possibility to achieve very early mCR with pembrolizumab.
The invention discloses a formula of a traditional Chinese medicine for reducing blood pressure. The traditional Chinese medicine comprises 5-10 parts of ligusticum wallichii, 10-15 parts of chrysanthemum, 5-10 parts of rhizoma alismatis, 10-15 parts of radix astragali, 5-10 parts of prunella vulgaris and 10-15 parts of lotus leaves. The preparation method of the traditional Chinese medicine comprises adding water into the above traditional Chinese medicines, wherein the use amount of the water is 2-3 times that of the traditional Chinese medicines, carrying out decoction for 2-3h and filtering the decoction to obtain soup. The traditional Chinese medicine can effectively reduce blood pressure. The traditional Chinese medicine can cure slight hypertension in one treatment course and cure severe hypertension in three treatment courses. The traditional Chinese medicine has substantial curative effects, a low recurrence rate and no toxic or side effect.
This is a multi-center, randomized, phase 2 study evaluating the efficacy, anti-tumor effect, and immunogenicity of neoadjuvant enoblituzumab given prior to radical prostatectomy in men with high-risk localized prostate cancer. Patients will be recruited from the outpatient Urology clinics and Multidisciplinary Prostate Cancer ("Precision Medicine") Clinics at four participating institutions including: Harvard/Dana-Farber Cancer Centers, Northwestern Lurie Comprehensive Cancer Center, Mayo Clinic, and the University of Minnesota Masonic Cancer Center. Eligible patients will undergo a pre-treatment prostate biopsy and conventional imaging (CT and bone scan) as well as PSMA-PET and optional prostate MRI as per institutional preferences. Patients who have N0 M0 disease by conventional imaging (N1 by PSMA allowed with up to 3 LNs each ≤1 cm) will be trial eligible as long as concurrent hormonal or radiation therapy is not given. Patients will then be randomized to enoblituzumab for a total of 12 weeks beginning 84 days prior to radical prostatectomy or SOC arms. Fourteen days after the last treatment, prostate glands will be harvested at radical prostatectomy, and prostate tissue will be examined for pathologic response and secondary pharmacodynamic/immunologic endpoints as described herein. Pre-treatment, on-treatment, and post-treatment biomarkers of response and resistance will be collected including: plasma, PBMC. Repeat PSMA scan will be obtained prior to radical prostatectomy. Follow-up evaluation for adverse events will occur 30 and 90 days after surgery. Patients will then be followed by the patient's urologists/oncologists according to standard institutional practices but will require PSA evaluations every 3 (±1) months during year 1 and every 6 (±2) months during years 2-3.
Once enrolled, participants will complete a baseline sampling session and then three sequences of study product administration, each with 3 douches. Sequence A will be 3 sequential doses of TFV douche; Sequence B will be one dose of TFV douche followed by 2 sequential non-medicated douches; Sequence C will be 2 sequential non-medicated douches followed by a single dose of TFV douche. There will be a washout period of at least 14 days between sequences. Participants will have sequences administered in clinic or a research unit, followed by various specimen collections over 8 days according to individual sampling schedule assigned to each participant. Specimens will be collected on Days 1, 2, 4, and 8 post sequence administration.
BACKGROUND: To evaluate the clinical significance of noninvasive prenatal testing (NIPT) for detecting fetal sex chromosome aneuploidies (SCAs) in Korean pregnant women.
METHODS: We retrospectively analyzed NIPT data from 9,176 women with singleton pregnancies referred to the CHA Biotech genome diagnostics center. Cell-free fetal DNA (cffDNA) was extracted from maternal peripheral blood, and high-throughput massively parallel sequencing was conducted. Subsequently, the positive NIPT results for SCA were validated via karyotype and chromosomal microarray analyses.
RESULTS: Overall, 46 cases were SCA positive after NIPT, including 20, 12, 8, and 6 for Turner, triple X, Klinefelter, and Jacob syndromes, respectively. Among 37 women with invasive prenatal diagnosis, 19 had true positive NIPT results. The overall positive predictive value (PPV) of NIPT for detecting SCAs was 51.35%. The PPV was 18.75% for Turner, 88.89% for triple X, 71.43% for Klinefelter, and 60.00% for Jacob's syndromes. NIPT accuracy for detecting sex chromosome trisomies was higher than that for sex chromosome monosomy (P = 0.002). No significant correlation was observed between fetal SCA incidence and maternal age (P = 0.914), except for the borderline significance of Jacob's syndrome (P = 0.048). No significant differences were observed when comparing NIPT and karyotyping validation for fetal SCA according to pregnancy characteristics.
CONCLUSION: Our data suggest that NIPT can reliably screen for SCAs, and it performed better in predicting sex chromosome trisomies compared with monosomy X. No correlation was observed between maternal age and fetal SCA incidence, and no association was observed between different pregnancy characteristics. The accuracy of these findings requires improvements; however, our study provides an important reference for clinical genetic counseling and further management. Larger scale studies, considering confounding factors, are required for accurate evaluation.
PURPOSE:To enhance sensitivity, by measuring the antibody titer of an immunized cattle or bovine leukemia virus (BLV) infected cattle by enzymatic antibody immunoassay using a plate to which protein derived from BLV is bonded as an antigen. CONSTITUTION:Inert protein occurring from BLV is preliminarily bonded to an antibody titer measuring plate in enzymatic antibody immunoassay as an antigen and the enzymatic antibody immunoassay is used to assay an antibody titer. Herein, the inert protein derived from BLV adsorbed by the plate is prepared by a method wherein crude protein containing BLV is prepared from a cultured cell of a BLV infected host cell or a culture solution thereof and, after the BLV of the crude protein is deactivated, a solution containing deactivated BLV-containing crude protein is treated with ultrafiltration to obtain a conc. fraction and the protein in said conc. fraction is adsorbed by the plate. As the host cell, a sheep cell or goat cell of FLK is used.
A 3+3 dose escalation design will be followed. Given the safety profile in prior trials, A dose of 250 mg weekly will be the starting dose. The first 12-15 patients are expected to receive escalating doses of ONC 201, the remaining patients will go on the expansion cohort.
This randomized controlled trial (RCT) with a longitudinal mixed-method process evaluation aims to (1) determine the effectiveness of a ZTEx intervention program, which is a lifestyle-integrated physical activity program, on sleep and related outcomes in inactive adults with insomnia disorder; (2) identify the facilitators and barriers of ZTEx adherence, (3) explore the possible mechanisms of impact on ZTEx adherence and the same abovementioned outcomes.

This RCT consists of two phases. In the first phase (baseline to week 8), 136 subjects will be randomly allocated to the ZTEx intervention or the sleep hygiene education (SHE) comparison group. They will receive two 2-hour ZTEx training or SHE lessons and practice ZTEx or follow the sleep hygiene instruction for 24 weeks. After assessment at week 8, for the second phase of the study (weeks 9-24), which is a proof-of-concept pilot nested in the RCT, subjects in the ZTEx group will be randomly divided into either an ZTEx with WhatsApp reminder (ZTEx+R) subgroup or an ZTEx without WhatsApp reminder (ZTEx alone) subgroup to evaluate the effects of WhatsApp reminders on exercise adherence and the same outcomes. Mixed methods process evaluation will be conducted. Post-training and post-follow-up qualitative focus group interviews will be conducted; facilitators, barriers, and mediators will be analyzed.